Dosage form
Pills
Composition
cabergoline 500 mcg

Auxiliary substances: lactose, L-leucine, magnesium stearate (Е572).
Pharmacological action
Dopamine receptor agonist. Cabergoline is a synthetic ergot alkaloid that is derived Ergoline, dopamine agonist with prolonged action, inhibiting the secretion of prolactin. The mechanism of action of cabergoline involves the stimulation of Central dopamine receptors of the hypothalamus. At doses higher than required to suppress the secretion of prolactin, the drug causes Central dopaminergic effect, due to stimulation of dopamine D2-receptors. The effect of the drug is dose dependent in nature. Decreasing the amount of prolactin in blood is usually observed after 3 h and persists for 2-3 weeks, in connection with than to suppress the secretion of milk is usually enough of a single dose of the drug. In the treatment of hyperprolactinemia prolactin content in normal blood after 2-4 weeks of using the drug in an effective dose. Normal levels of prolactin can persist for months after discontinuation of the drug.

Cabergoline has a highly selective effect and no effect on basal secretion of other pituitary hormones and cortisol. The only pharmacodynamic effect linked to therapeutic effect is a decrease in blood pressure. The maximum hypotensive effect usually develops within 6 h after a single dose of the drug; the degree of blood pressure reduction and incidence of hypotensive effect dose-dependent.

Contraindications
postpartum or uncontrolled hypertension;

— severe disturbances of liver function;

— adverse events from the lungs such as pleuritis or fibrosis (including in history), associated with the use of dopamine agonists;

— psychosis (W. in history) or the risk of development;

— pregnancy and developed on the background of preeclampsia and eclampsia;

— lactation (breastfeeding);

— hypersensitivity to cabergoline, other ergot alkaloids or any component of the drug.

The efficacy and safety of the use of cabergoline in children under 16 years of age have not been studied.

With caution should appoint drug patients with cardiovascular disease, hypotension, Raynaud's syndrome, peptic ulcers or gastrointestinal bleeding, patients with end-stage renal failure or on hemodialysis, elderly patients
Drug interactions
Influence of macrolide antibiotics on the plasma of cabergoline in combination has not been studied. Given the possibility of increasing the level of cabergoline, the drug is not recommended for use in combination with macrolides.

The mechanism of action of cabergoline is associated with direct stimulation of dopamine receptors, so it should not be used in combination with antagonists of dopamine receptors (phenothiazines, butyrophenone, thioxanthene, metoclopramide).

There is no information on interactions of cabergoline with other ergot alkaloids, however, we do not recommend prolonged use of this combination.

Given the pharmacodynamics of cabergoline (hypotensive effect), it is necessary to take into account the interaction with drugs that reduce blood pressure.

In clinical studies in patients with Parkinson's disease pharmacokinetic interaction with levodopa or selegiline was not detected.